Trading a AGIO straddle lets you take a pure volatility position on Agios Pharmaceuticals Inc without committing to a direction. Agios Pharmaceuticals Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate AGIO straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on AGIO profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Agios Pharmaceuticals Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the AGIO straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the AGIO straddle is the cleanest expression of that view. Our scanner prices every AGIO straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a AGIO straddle into a catalyst or short a AGIO straddle to harvest decay, the options straddle setups that matter are all in one place.
